Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

38.77 +2.46 (+6.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
CRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholders 
Via MarketBeat
Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?
Via The Motley Fool
2 Biotech Stocks That Are Screaming Buys in May
Via The Motley Fool
Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire?
The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline. 
Via The Motley Fool
3 Monster Stocks to Hold for the Next 10 Years
The planets are lining up for these three stocks' underlying companies. 
Via The Motley Fool
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
In a rising market, the iconic growth investor is adding to positions trading well below their earlier highs. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025. 
Via Benzinga
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
Exposures Product Safety
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results
Via Benzinga
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks
The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program. 
Via Investor's Business Daily
Topics Government Intellectual Property
Exposures Intellectual Property Political
Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant
On Wednesday, April 30, 2025, Cathie Wood sold $2.65 million worth of Palantir shares through various ARK ETFs. 
Via Benzinga
2 Beaten-Down Stocks With Incredible Upside Potential
Via The Motley Fool
5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years
Via The Motley Fool
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
3 Magnificent Stocks That Could Double or More by 2030
Via The Motley Fool
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The iconic growth investor made some interesting moves during Friday's market pullback. 
Via The Motley Fool
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox
Via Benzinga
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
Via The Motley Fool
Topics Bankruptcy Economy World Trade
Exposures Economy Financial Legal
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Via The Motley Fool
Topics Government World Trade
Exposures COVID-19 Political Product Safety
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies. 
Via Investor's Business Daily
Exposures Product Safety
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
2 Beaten-Down Stocks to Buy on the Dip
Via The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
Via The Motley Fool
Cathie Wood Stands By Tesla's $2,600 Price Target Despite 40% Stock Drop: 'It's Winner Take Most
Via Benzinga
Cathie Wood's Ark Invest Continues To Load Up On Tempus AI, Dumps Bitcoin-Focused Block In Tech Meltdown Aftermath
On Tuesday, Cathie Wood‘s Ark Invest executed notable trades, including significant activity involving Tempus AI Inc. (NASDAQ:TEM), Block Inc. (NYSE:XYZ), and DraftKings Inc.< 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Via The Motley Fool
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS